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Early effects of gentamicin, tobramycin, and amikacin on the human
kidney. The early alterations at the level of the proximal tubule of the
human kidney caused by the three most currently used aminoglyco-
sides, gentamicin, tobramycin, and amikacin, were studied. A prospec-
tive, randomized, and comparative approach using multidisciplinary
methods was used. The patients received either no treatment or one of
the three aminoglycosides at a therapeutic dose for 4 days preceeding
nephrectomy for neoplasia partly involving one kidney. The three
aminoglycosides studied induce an early lysosomal phospholipidosis.
Gentamicin and tobramycin cannot be distinguished on the basis of drug
tissue accumulation, lysosomal overloading, or effect on lysosomal
phospholipase Al. Amikacin induces significantly lower lysosomal
overloading and no loss of phospholipase Al activity.
Effets précoces de Ia gentamicine, de Ia tobramycine, et de l'amikacine
sur le rein humain. Les alterations précoces au niveau du tubule
proximal dans le rein humain, entraInées par les trois aminoglycosides
les plus utilisCs, Ia gentamicine, Ia tobramycine, et l'amikacine ont été
étudiées. Une approche prospective, randomisee, et comparative,
utilisant des méthodes multidisciplinaires a été employee. Les malades
ont recu soit aucun traitement, soit un des trois aminoglycosides a une
dose thérapeutique pendant 4 jours avant une néphrectomie pour
nCoplasie touchant partiellement un rein. Les trois aminoglycosides
étudiés induisent une phospholipidose lysosomiale précoce. La genta-
micine et Ia tobramycine ne peuvent pas être distinguees sur Ia base de
leur accumulation tissulaire, de Ia surcharge lysosomiale, ou de leur
effet sur La phospholipase Al lysosomiale. L'amikacine induit une
surcharge lysosomiale significativement plus faible et n'entraine pas de
perte d'activité de La phospholipase Al.
Aminoglycosides remain useful and widely used antibiotics
for the treatment of severe bacterial infections despite well
documented oto- and nephrotoxicity [1]. Since tobramycin and
amikacin were introduced, much attention has been given to
studies comparing the effectiveness and toxicity of these drugs
with the earlier and still frequently used aminoglycoside
gentamicin,
Regarding nephrotoxicity, the results of studies in humans
have so far been inconclusive [2, 31. Moreover, the reported
incidence of nephrotoxic reaction of the same antibiotic differs
from one study to another even when performed by the same
investigator at an interval of a few years [2, 4]. One reason for
these contradictory reports is the limited sensitivity of the most
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commonly used indicator of aminoglycoside nephrotoxicity,
that is, the increase in serum creatinine. Extensive alteration of
proximal tubular cells can be observed long before this parame-
ter is modified [5].
In recent years considerable progress has been made in
understanding the mechanism of the tubular alterations induced
by aminoglycosides. Animal studies have shown that gentami-
cm is adsorbed by pinocytosis and stored in the lysosomes of
proximal tubular cells [6, 7]. The earliest morphological alter-
ations at therapeutic dose concern the lysosomes of tubular
cells which accumulate electron-dense lamellar material (my-
eloid bodies) consisting of phospholipids [8—11]. This phospho-
lipidosis is caused by a decrease of the activity of lysosomal
phospholipases A as shown both in vitro and in vivo, and a
subsequent decrease in the activity of lysosomal sphingomye-
linase [11—13]. Increased dose or prolonged treatment with
aminoglycosides induces an array of tubular alterations which
have been described extensively (see [14] for review) and
includes the release of brush border and lysosomal enzymes,
mitochondrial alterations, focal tubular necrosis and regenera-
tion, and alteration of the tubular function. Associated with
them is a decrease in the GFR [15, 16], an increase in BUN, and
a hypo-osmotic polyuria [8, 17, 18].
The present study was designed to investigate early alter-
ations of the proximal tubule of the human kidney caused by the
three most frequently used aminoglycosides, gentamicin, tobra-
mycin, and amikacin. We used a prospective, randomized, and
comparative approach with multidisciplinary methods.
Methods
The whole protocol of this study was examined and found
ethically acceptable by the ad-hoc committee at the major
participating hospitals, that is, University Hospital Antwerp
and General Hospital Stuivenberg, Antwerp.
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Patients. Patients were of both sexes and their ages varied
from 30 to 72 years. All had neoplasia that partly involved one
kidney, as ascertained by arteriography, with normal glomeru-
tar filtration (creatinine clearance), normal cardiovascular sta-
tus, and clinically insignificant proteinuria (less than 300 mg/24
hr). Patients were excluded from the protocol if one of the
following features was present: a major metabolic disorder (for
example, diabetes); a concurrent infection; administration of an
aminoglycoside within the previous 4 months; administration of
drugs reported to affect lipid metabolism in lysosomes (antide-
pressants, anorexigens, chloroquine, and other antimalaric
agents; erythromycin, clindamycin, and basic antibiotics; lipid
soluble cardiotonic and anti-arrythmic drugs; and prostaglandin
inhibitors such as nonsteroidal anti-inflammatory drugs); ad-
ministration of drugs or other agents that accumulate in or may
affect kidney lysosomes (mannitol, dextran, polyvinylpirroli-
done, and other macromolecules, and "intralipid" and related
nutrition therapies) within the previous month; administration
of diuretics or other renal-acting drugs less than 1 week before
the study.
The patients, in four groups of six, received either no
treatment or one of the three aminoglycosides daily for the 4
days preceeding nephrectomy. Gentamicin and tobramycin
were given in a dose of 1.5 mg/kg three times a day, and
amikacin in a dose of 7.5 mg/kg two times a day according to the
manufacturer's recommendations and common clinical use.
The drug was administered intravenously in approximately 10
ml of saline over 15 mm. The study lasted 18 months. The
patients were allocated at random to either the treated or the
control group throughout that period. Serum and urine samples
were collected prior to therapy to assure the absence of
aminoglycosides. Before the first injection and thereafter before
each morning dose, a blood sample was taken for antibiotic
assay. The last dose was administered at least 14 hr before
surgery. Plasma creatinine and electrolytes were determined
daily during the study period.
Renal tissue sampling. All the renal cortical specimens were
taken from macroscopically normal tissue, that is, as far
removed as possible from the tumoral mass. The first surgical
biopsy specimen, obtained before clamping of the vessels, was
divided into four parts for light microscopical, ultrastructural,
immunofluorescence, and histochemical studies.
Within minutes after the nephrectomy several other cortical
specimens were taken, weighed, wrapped in paraffin (Para-
film,® American Can Company, Greenwich, Connecticut), fro-
zen in dry ice, and stored in small containers in a —30°C freezer
for antibiotic assay and biochemical analysis.
Antibiotic assay. The renal tissue samples were prepared
using an adaptation of the method of Kornguth and Kunin [19].
The previously weighed tissue samples (approximately 100 mg)
were thawed and homogenized in 10 m phosphate buffer (pH
7.4) using a cooled Potter-Elvehjem homogenizer at 1000 rpm
(four times twelve strokes). During the third and fourth steps,
the homogenate was acidified with trichloroacetic acid to obtain
protein denaturation and release of the antibiotic which might
be absorbed to the container's glass wall. After centrifugation
(x l200g, 20 mm) the supernatant (22 0.7 ml, mean SEM)
was titrated to pH 6.5 to 7.5 with 10% sodium hydroxide. Re-
extraction of the final discarded pellet did not yield any further
antibiotic. Aminoglycoside concentrations in serum and tissue
extracts were measured by radioimmunoassay (Gentamicin and
Tobramycin Gammacoat [12511 RIA kit, Clinical Assays, Cam-
bridge, Massachusetts; [125J] Amikacin RIA kit, Diagnostic
Products Corporation, Los Angeles, California). The detection
level was 0.2 g/ml for gentamicin and tobramycin and 0.4
g/ml for amikacin. For ten assays of the same homogenate the
coefficient of variation was 2.6% for gentamicin, 2.3% for
tobramycin, and 2.8% for amikacin. For assays of homogenates
obtained from eight different biopsy specimens of the same
kidney, the coefficient of variation was 3.2% for gentamicin,
3.1% for tobramycin, and 5.0% for amikacin. The addition of
known amounts of gentamicin, tobramycin, and amikacin to
control tissue homogenates submitted to the whole extraction
procedure and RIA determination showed a recovery of 82.5%
0.3 (mean sEM), 88.7% 0.5 (mean SEM), and 86.4%
0.7 (mean SEM) for gentamicin, tobramycin, and amikacin,
respectively.
Immunofluorescent localization of aminoglycosides. Immu-
nofluorescent localization of aminoglycosides was investigated
in two patients of each of the four groups. Three renal biopsy
specimens of untreated patients served as control subjects.
Slices, 1-mm thick, of renal cortex were snap-frozen in isopen-
tane cooled to near liquid nitrogen temperature and stored at
—70°C. Sections, 5-p,m thick, were prepared and freeze-dried in
a cryostat at —50°C (Wedeen, Refrigeration for Science, Island
Park, New York), fixed in acetone followed by 95% ethanol,
and washed in phosphate-buffered saline (pH 7.2) as previously
described [20]. Rabbit antibodies to gentamicin and goat anti-
bodies to tobramycin or amikacin (Miles Laboratories, Elkhart,
Indiana) were applied to the freeze-dried, fixed sections fol-
lowed by fluorescein isothiocyanate (FITC) goat anti-rabbit IgG
or FITC rabbit anti-goat IgG. Immunofluorescence microscopy
was performed with a research microscope (Carl Zeiss, Oberko-
chen, West Germany) using epi-illumination. The control sec-
tions from untreated human kidneys did not show fluorescence
under these conditions. No staining was seen when either FITC
goat anti-rabbit IgG or FITC rabbit anti-goat IgG was used
alone. Indirect fluorescence microscopy was also negative
(rabbit anti-human lgG was followed by FITC goat anti-rabbit
IgG).
Histochemical studies. For acid phosphatase staining, the
samples were fixed in cold 2% glutaraldehyde-0. I M sodium
cacodylate buffer and rinsed overnight in cacodylate buffer-
7.5% sucrose. Cryostat sections, 7 sm, were incubated at room
temperature, with naphtol AS-TR phosphate at pH 5 [21] and
examined under a light microscope. For electron microscopy
50-pm unfrozen sections were incubated with J3-glycerophos-
phate [22] for 1 hr at 37°C, postfixed with osmium tetroxide, and
processed as described below. Incubations were also performed
in the presence of 0.01 M sodium fluoride, which inhibits acid
phosphatase activity.
To detect brushborder enzymes, cryostat sections were
stained for y-glutamyl-transferase [23], leucine aminopeptidase
[24], and alkaline phosphatase [25], and examined by light
microscopy.
Morphological studies, For light microscopy, the tissue sam-
ples were fixed in Dubosq-Brazil and stained with Hematoxy-
lin-Eosin (H & E) and Periodic acid-Schiff reagent. Cryostal
sections from unfixed samples were used for immunofluores
cence (detection of IgG, IgA, 1gM, fibrin, and C'3). For
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electron microscopy, the samples were fixed in 2% glutaralde-
hyde in 0.1 M sodium cacodylate (pH 7.4), postfixed in 2%
0s04 in Veronal acetate buffer (pH 7.4), block-stained with 2%
uranyl acetate, and embedded in Epon 812. Ultrathin sections
(approximately 60-nm thick) were stained with lead citrate and
examined with an electron microscope (Zeiss EM 109) at 80 kV,
Morphometry was performed according to methods de-
scribed by Weibel [261. Ultrathin sections were obtained from
two different randomly chosen blocks of cortical tissue. For
each block, a first series of micrographs was taken from all
proximal tubular profiles in one section; care was taken to
include the whole height of the proximal tubular cell. A second
series of micrographs was taken from another section; it was
cut at a distance of at least 5m from the preceeding one.
Positive prints were made on transparent sheets (Copyline
HDU, Agfa-Gevaerte, Marksem, Belgium) at a magnification of
exactly x 10,000 and examined on a viewer. Exact magnifica-
tion was determined with a calibration grid of 2,160 lines/mm.
The scanned surface of proximal tubular profiles of each
individual patient varied between 2.961 and 6.252 tIm2.
The following data were calculated for each patient: (1) the
percentage of the total cell volume occupied by lysosomes, by
superimposing a lattice of equidistant points (1/2.25m2 of cell
profile) on the prints and counting the proportion of points
hitting the lysosomal profiles; (2) the percentage of the lysosom-
al volume occupied by dense lamellae by superimposing a
lattice of equidistant points (25points/,am2 of lysosomal profile)
on the prints and counting the number of points falling over
dense lamellae. The volume occupied by dense lamellae, as a
percentage of the total cell volume, was calculated from these
data.
Biochemical analyses. Biopsy specimens were cut in several
small pieces, weighed and homogenized in distilled water at 0°C
with an all-glass conical tissue grinder fitted with a ground
pestle, and brought to a final dilution of 20 mg of wet tissue per
milliliter. At least three distinct homogenates were made from
each biopsy specimen.
Lysosomal phospholipase Al (phospholipid 1-deacylase, EC
3.1.1.32) was assayed at pH 4.0 as described by Laurent et al
[13] using '4C-labelled phosphatidyl choline. The coefficients of
variation were: for ten assays of the same homogenate, 4.7%;
for triplicate assays of ten homogenates from the same biopsy
specimen, 9.7%; for triplicate assays of homogenates obtained
from ten different biopsy specimens from the same kidney,
21.9%. Lysosomal sphingomyelinase (sphingomyelin phospho-
diesterase, EC 3.1.4.12) was assayed with bovine '4C-labelled
sphingomyelin [13, 27]. The other lysosomal enzymes (3-N-
acetyl-hexosaminidase, EC 3.2.1.30; cathepsin B, EC 3.4.22.1;
acid phosphatase, EC 3.1.3.2) and the non-lysosomal enzymes
(glucose 6-phosphatase, EC 3.1.3.9); alanylaminopeptidase, EC
3.4.11.2; glycogenphosphorylase, EC 2.4.2.2); proteins and
lipid phosphorus were assayed by standard procedures [28—30].
Enzyme activities are expressed in standard milliunits (nano-
moles of substrate converted per minute) per milligram of tissue
protein.
Statistical analysis. The data were analyzed for statistically
significant differences among groups by the Kruskal-Wallis one-
way analysis of variance by ranks. If significance was obtained,
the groups were tested two by two with the Mann-Whitney U
test [31].
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Fig. 1. Renal cortical concentration (/.Lg/g cortical tissue) of gentami-
cm, tobramycin, and amikacin after 4 days of administration at a
therapeutic dose. The numbers at the bottom of the figure refer to
patients.
Results
Traces of drugs were not found in the serum or in the urine of
any of the patients before the start of the aminoglycoside
treatment. Thereafter, the plasma levels determined each day
before the first injection (trough levels) were below 2 tg/ml for
gentamicin and tobramycin and below S g/ml for amikacin. No
change in plasma creatinine and electrolytes was detected after
the 4-day treatment period for any aminoglycoside studied.
Figure 1 shows the cortical concentration of the three ami-
noglycosides (at least a duplicate determination in three sam-
ples for each patient). The accumulation of gentamicin and
tobramycin is comparable, whereas that of amikacin is signifi-
cantly higher (P < 0.001, Table 1). The serum drug level at the
time of the renal biopsy was below 1.5 tg/ml forgentamicin and
tobramycin and below 4 g/ml for amikacin.
Figure 2 shows the cortical distribution of gentamicin by
indirect immunofluorescence. The drug was found in variably
sized granular structures in the cytoplasm of the proximal
tubular cells. The glomeruli, distal tubules, and vascular endo-
thelium showed no fluorescence. A similar antibiotic distribu-
tion was observed in the tobramycin and the amikacin-treated
patients.
Figure 3A and B show that treatment with aminoglycosides
alters lysosomes in the proximal tubule, as detected by histo-
chemical staining for acid phosphatase in light microscopy. The
lysosomal stain was more intense, so that all the biopsy
specimens from treated patients could be distinguished from
those of the control subjects. A large variation was, however,
found throughout the cortical tissue and between specimens of
the treated patients. Ultrastructural analysis (Fig. 3C and D)
shows that the acid phosphatase reaction product is observed in
single-membrane-bound bodies (lysosomes) in the control sub-
jects as well as in the treated patients.
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Table 1. Statistical analysis of data shown in Figures 1, 5 and 6
Kruskal-
Wallis
test
Mann-Whitney test
C-G C-T C—A G—T G—A T-A
Antibiotic concentration in
renal cortex 0.01 — — — NS 0.01 0.01
Lysosomal volume 0.01 0,05 0.01 0.01 NS NS NS
Lamellar volume 0.01 0.01 0.01 0.01 NS 0.01 0.01
Phospholipase Al 0.01 0.01 0.01 NS NS 0.01 0.01
Abbreviations and symbols: C, control; G, gentamicin; T, tobramycin; A, amikacin; —, irrelevant; NS, no significant difference (P > 0.05).
Fig. 2. Lysosomal localization of aminoglycosides in the proximal
tubule. The section was obtained from a biopsy specimen of gentami-
cm-treated patient no. 5 and reacted with rabbit anti-gentamicin anti-
bodies; indirect immunofluorescence was performed with FITC-conju-
gated anti-rabbit lgG. (x300)
In the control subjects, the content of lysosomes was other-
wise homogenous and moderately osmiophilic, whereas promi-
nent lamellar structures were present in the treated patients.
The ultrastructural alterations are shown in more detail in
Figure 4. Almost every lysosome contained lamellar, concen-
tric material with a periodic pattern of 5 nm (Fig. 4A), which is
considered to consist of phospholipids [281. The lysosomes and
lysosomal content were analyzed by morphometry. As illustrat-
ed in Figure 5, the lysosomal volume increased in most of the
patients receiving aminoglycosides. The lower part of Figure 5
shows that gentamicin- and tobramycin-treated patients display
a large amount of lamellar material in lysosomes. This was also
observed in the lysosomes of amikacin-treated patients, but to a
lesser extent in five of the six patients of this group; the
difference was statistically significant (P < 0.01, Table 1).
Lamellar material was extremely rare in the untreated pa-
tients. The occasional osmiophilic bodies found in the lyso-
somes lacked the typical 5 nm pattern. The other organelles
showed no significant alterations. In particular the mitochon-
dna retained their normal appearance and shape, and their
relative volume was unchanged when treated (no significant
difference by the Kruskal-Wallis test). The brush border re-
mained unaltered, as judged by its appearance in electron
microscopy and after staining for y-glutamyl-transferase, leu-
cine aminopeptidase, and alkaline phosphatase in optic micros-
copy. In electron microscopy, however, the proximal tubular
lumen of all treated patients contained numerous membrane
"whorls" of lamellar structure, with a concentric disposition
but an irregular pattern (Fig. 4B). This was almost never seen in
the control patients.
Immunofluorescence for IgG, 1gM, IgA, fibrin, and C'3
revealed no consistent differences between the treated and the
untreated patients. Examination of H & E sections failed to
reveal any alteration related to aminoglycoside treatment.
The biochemical analysis showed a significant influence of
the treatment with gentanlicin or tobramycin on the activity of
lysosomal phospholipase Al (Fig. 6). In both groups, five out of
the six patients displayed activities lower than control values by
more than 2 SD. Reassay of the low activity samples gave
results consistent with the first determinations. In the amikacin
group, five patients had a normal value and one showed an
increased activity. The mean activity of the six control patients
was in the range observed in a larger number of control patients
(N = 16) studied by biochemical methods only (1.085 0.185
(SD) mU/ml protein). The activity of sphingomyelinase showed
no significant difference between the control subjects and
aminoglycoside-treated patients. Other enzyme activities were
also unaffected by the treatment (lysosomes, /3-N-acetylhexosa-
minidase, cathepsin B, acid phosphatase; endoplasmic reticu-
lum, glucose 6-phosphatase; brush border, alanylaminopepti-
dase; cytosol, phosphorylase).
Finally, there was no significant increase of total lipid phos-
phorus in the treated patients (control values, 19.7 4.4
,amoles/g of tissue, N = 10; gentamicin, 22.4 2.7 Lmoles/g of
tissue, N 6; tobramycin, 21.8 3.3 xmoles/g of tissue, N =6;
amikacin, 20.9 2.2 xmoles/g of tissue, N = 6; values
expressed are means SD).
Discussion
Aims, means, and limitations of the study
Our first aim was to determine whether significant, consistent
alterations are present in the proximal tubular cells of humans
receiving therapeutic doses of aminoglycosides before the onset
of excretory failure. The three most frequently used aminogly-
cosides were compared in this respect under strictly controlled
conditions.
To our knowledge, no established, simple, and reliable test of
the integrity of proximal tubular cells is available in clinical
practice. Tests of early tubular dysfunction (for example,
excretion or /3-2-microglobulin) or of tubular necrosis or insult
(for example, enzymuria of cast-counts) do indeed show patho-
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Fig. 3. Histochemistry (acid phosphatase) of proximal tubule in control and treated patients. Light microscopy: panel A, control patient (x360);
panel B,patientno. 5 tobramycin (x360). The increase of reaction product in the treated kidney was seen. Heterogeneity between tubular sections
was striking. Lower panels: electron microscopy; the reaction product was evenly distributed in lysosomes; panel C, control patient: panel D,
patient no. 4 lobramycin; the lysosomes contain prominent lamellar structures. The bar in panels C and D represents I m.
logic values in a large proportion of patients treated with
aminoglycosides [1]. Because of the high variations among
individual patients and the unspecific character of these param-
eters, however, these tests have little diagnostic or prognostic
values [32], The disease state of the patients, concomitant
therapies, and the absence of adequate controls moreover have
not allowed definitive conclusions. The present study repre-
sents to the best of our knowledge the first prospective effort
using normal renal tissue to clearly identify the parameters
modified by aminoglycosides in humans.
For ethical reasons the patients could only receive the drugs
under conditions minimizing the risk of functional alteration of
the kidney. Also, ototoxicity had to be avoided. Therefore, our
investigation is limited to the detection of the earliest biochemi-
cal and morphological alterations.
In contrast to patients with pyelonephritis, hydronephrosis,
pyelum tumors, and other surgical indications, patients with a
neoplasia partly involving one kidney still maintain normal
cortical tissue that can readily be obtained during surgery.
None of our patients showed urinary excretion of aminoglyco-
sides prior to the study, thereby confirming historical informa-
tion that they had not recently been exposed to these drugs.
Protracted urinary excretion of detectable amounts of ami-
noglycosides indeed occurs for weeks after administration [33].
We did not investigate the urinary excretion of enzymes from
the brush border or lysosomes, or the excretion of 13-2-micro-
globulin or lysozyme, since renal tumors are known to affect
these parameters [34]. Both untreated and treated patients have
received the same amount of radiographic contrast media.
Glomerular-tubular imbalance due to tumoral hyperemia [35]
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Fig. 4. Ultrastructural appearance of proximal tubular cells in aminoglycoside-treated patients (4 days at therapeutic dose). A Lysosomes (large
arrow) contain dense lamellar and concentric structures. Brush border, mitochondria (small arrow) and peroxisomes are unaltered. Upon higher
magnification the structures in lysosomes show a periodic pattern. The bar in the upper part represents I m, in the lower part 0.1 j.m. B Apical
portion of proximal tubular cell with brush border (small arrow) and part of tubular lumen, containing loosely arranged membrane whorls (large
arrow). The bar represents I sm.
should not be considered since biopsy specimens were taken at
a distance from neoplastic tissue. Our study was also prospec-
tive, which allowed an unambiguous interpretation of the
alterations seen, in contrast to a previous report describing
myeloid bodies in lysosomes of gentamicin-treated patients
[36].
Accumulation and localization of aminoglycosides
We found similar cortical concentrations for gentamicin and
tobramycin and values approximately three times larger for
amikacin. When expressed as the fraction of the administered
dose, however, no significant difference was observed between
the three antibiotics, which suggests each was handled similarly
by the human kidney. This finding contrasts with the data of
Schentag, Plaut, and Cerra [37], indicating a lower accumula-
tion of tobramycin in humans. However, in the latter study, the
treatments varied in time and dose, the patients received many
other therapies and the analyses were performed on postmor-
tem samples.
Animal studies have shown that gentamicin accumulates in
lysosomes [6, 71. Our data obtained by indirect immunofluores-
cence detection are compatible with a similar localization in
human kidney. In a concomitant study by Wedeen et al [38] a
combined immunofluorescent and autoradiographic localization
of 3H-gentamicin was used in animals. The same lysosomal
localization was seen 6 hr after a single injection; there was
minimal displacement of gentamicin into the interstitial space
during processing for immunofluorescent examination [38].
Since the bulk of the aminoglycoside is trapped in the
lysosomes, we may conclude that it must be highly concentrat-
ed in these organelles. Taking the lysosomal volume to be an
average of 4% of cell volume in treated patients (Fig. 5), it can
easily be calculated that the accumulation levels shown in
Figure 1 should correspond to intralysosomal concentrations of
approximately 5,000 to 12,000 g/g or more since the drug is
localized almost exclusively in proximal tubules.
Alterations of lysosomes
Histochemistry revealed significant alterations of lysosomes.
These can be interpreted as an increase in volume or density or
an enhancement of acid phosphatase activity [391. Electron
microscopy showed that the volume of lysosomes is significant-
ly increased after treatment with all three aminoglycosides. In
addition, lysosomes contain lamellar, osmiophilic material simi-
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Fig. 5. Comparative quantitative analysis of the volume of lysosomes
and lamellar structures in proximal tubular cells of untreated and
amino glycoside-treated patients.
tar to the one found in animals [8—10] or in fibroblasts exposed
to gentamicin [28]. The appearance of this material and its
periodic pattern is that of layers of polar lipids [40].
Animal [10, 13] and fibroblast studies [28] have evidenced an
excess of phospholipids after gentamicin treatment which re-
suits most likely from an impairment of the activity of lysosom-
al phospholipases. We showed in vitro that aminoglycosides
bind to phospholipid bilayers under conditions similar to those
prevailing in lysosomes in vivo [13], that is, at an acid pH and in
the presence of phosphatidyi inositol [4 1—44]. This binding
causes an inhibition of lysosomal phospholipases Al, A2, and C
[12, 13]. A significant inhibition of tysosomal phospholipase Al
from animal kidney cortex has been demonstrated after treat-
ment at low doses of gentamicin [10, 13]. The present study
shows that gentamicin and tobramycin induce a clear-cut and
similar loss of activity of the same enzyme in humans. Other
lysosomal enzymes, including acid phosphatase, showed no
change in activity. The lack of significant, consistent effects of
the gentamicin treatment on sphingomyelinase activity is puz-
zling at first glance. Sphingomyelinase is the first enzyme for
which a loss of activity was described after gentamicin treat-
ment in animals [45] or cultured fibroblasts [28]. We have
recently shown, however, that impairment of sphingomyelinase
activity is a secondary effect of phospholipid accumulation in
lysosomes [13]. We have also reported that patients who
received prolonged treatment with gentamicin show a signifi-
cant decrease of the activities of both phospholipase Al and
sphingomyelinase [11]. The failure to detect an increase of total
lipid phosphorus in patients treated 4 days does not contradict
the concept that aminoglycosides induce a lysosomal phospho-
lipidosis [28, 46]. Phospholipids are constituents of all mem-
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Fig. 6. Activity of lysosomal phospholipases Al in kidney cortex of
untreated and aminoglycoside-treated patients. Results are similar if
activity is expressed per gram of tissue wet weight.
branes and these are very abundant in tubular cells. The
lamellar material found in lysosomes of proximal tubular cells is
about 0.6% of the cell volume. Assuming that it is made entirely
of phospholipids organized in bilayers, this represents an ex-
cess of approximately 3 tmoles/cm3 of cell [47], a value that
falls within the variation range shown for control patients. In
rats, where control subjects show less variation, a clear-cut
excess of phospholipids has been demonstrated after 7 days of a
therapeutic dose of gentamicin [10, 13].
At this stage of the treatment we have not found evidence of
alteration of other subcellular structures except lysosomes.
Activities of marker enzymes for endoplasmic reticulum, cyto-
sol or brush border were unaffected. No morphological alter-
ations of these structures or of mitochondria was observed.
Histochemistry of the brushborder enzymes, including alkaline
phosphatase, was normal. It has been reported that aminogly-
cosides bind to acidic phospholipids in vitro (for review, [48])
and disturb the activities of membrane enzymes dependent on a
phospholipid environment [49]. We have not specifically looked
for these effects, since their demonstration in vivo requires
treatment with high, nontherapeutic doses [50] in contrast with
the effects seen on lysosomes. On the other hand, the presence
of lamellar material in the lumen (membrane whorls) suggests
some degree of exocytosis [51] and/or cell necrosis. This may
be the basis for the early increased excretion of lysosomal and
brushborder enzymes reported by many investigators [1, 14, 17,
52].
Gentamicin and tobramycin are indistinguishable, with re-
spect to cortical drug accumulation, accumulation of lamellar
material, and decrease of phospholipase Al activity. This
contrasts with amikacin. Despite its higher renal cortical con-
centration, this drug is associated with significantly less accu-
mulation of lamellar material and no detectable effect on
phospholipase Al activity.
Toxicological and clinical implications
The relationship between the alterations that develop early
during therapy and subsequent renal dysfunction has been
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studied in several systems. Animal studies have demonstrated a
sequence of events (time- and dose-dependent) going from
lysosomal alterations, tubular dysfunction, focal cell necrosis,
and luminal obstruction up to late renal excretory failure [8, 9,
53]. This pattern has also been observed in humans [11, 54]. In
cultured cells exposed to gentamicin [28], cell lysis is observed
when lysosomal overloading becomes extensive. The relation-
ship between lysosomal alterations and cell death is not estab-
lished, but a possible mechanism is the rupture of lysosomes
with the release of potentially injurying enzymes and large
amounts of aminoglycosides in cytosol. An important, although
indirect indication that lysosomal dysfunction is a valuable
index, if not a step, in aminoglyco side-induced nephrotoxicity,
has been given by comparative studies in animals. Thus,
amikacin, tobramycin, and gentamicin were compared at the
level of lysosomal alterations for up to 14 days and at low,
equitherapeutic doses [55, 561. The toxicity ranking (amikacin
<tobramycin < gentamicin) paralleled the one found indepen-
dently in a histological evaluation made after prolonged expo-
sure (28 days) to one to five times the therapeutic dose [58]. A
lesser toxicity of amikacin was also found on the basis of
histological or functional criteria upon acute administration of
high doses [55, 58]. Recently, Wilmotte et al [59] investigated
two derivatives of gentamicin, one more and one less toxic than
the parent drug, respectively, based on histological and physio-
pathological criteria; these differences were reflected in the
degree of the early lysosomal alterations.
Other drugs, chemically unrelated to aminoglycosides, (for
example, tricyclic antidepressants, clindamycin, and in general,
amphiphilic, cationic drugs) also induce lysosomal phospholipi-
dosis (for a review [40, 60]). The two kinds of compounds
cannot, however, be compared directly. In contrast to ami-
noglycosides, doses much higher than therapeutic doses, or
chronic administration for weeks, are necessary to cause these
effects. Moreover, these lipophilic drugs enter cells by permea-
tion/diffusion and bind to all cellular membranes, including the
endoplasmic reticulum, besides their association with lyso-
somes [59]. The phospholipidosis which they induce is even not
entirely restricted to lysosomes [61]. Furthermore, these drugs
also have a much broader distribution in the body and affect
several organs [59].
Other mechanisms of aminoglycosides toxicity toward proxi-
mal tubular cells, independent of lysosomes, have been postu-
lated: such as inhibition of "phosphatidyl inositol response"
[46, 63], mitochondria dysfunction [64], or inhibition of Na/K
ATPase [501. These mechanisms are based on in vitro studies,
with optimal contact between the drug and the investigated
enzyme or structure. The corresponding effects, however, have
not been shown to occur early in vivo at therapeutic doses. This
is understandable since the renal handling of aminoglycosides
restricts the access of these hydrophilic drugs to apical mem-
brane, endocytic vacuoles and lysosomes, at least in the initial
stage [7]. The above mechanisms may undoubtedly play a role if
aminoglycosides are liberated from lysosomes at a later stage.
Bayliss, Rennke, and Brenner [151 have shown that gentami-.
cm decreases the glomerular ultrafiltration coefficient in addi-
tion to its action on the proximal tubules and that this effect is
abolished by captopril [16]. The significance of this observation
in the onset of tubular necrosis remains an open question, since
it has not been confirmed in other studies [65]. Moreover, the
doses needed are much larger (40 mg/kg) than those used in
clinical practice or in the animal studies which reveal the
lysosomal alterations [8, 10—13, 56, 59, 66].
Conclusions
Gentamicin, tobramycin, and amikacin, at therapeutic dose,
induce in the human kidney cortex an early lysosomal phospho-
lipidosis comparable to that observed in animals treated with
low doses of these drugs. After 4 days of treatment, gentamicin
and tobramycin cannot be distinguished on the basis of cortical
drug accumulation, lysosomal overloading, and effect on lyso-
somal phospholipase Al. Using the recommended clinical dos-
age, amikacin induces significantly less lysosomal overloading
than gentarnicin or tobramycin and no loss of phospholipase Al
activity. In a recent study, using an identical protocol [67],
netilmicin was found to behave between gentamicin, tobramy-
cm, and amikacin. In cultured cells [68] or animals treated at
therapeutic doses [55, 561 amikacin showed a lesser effect on
proximal tubules compared to the other aminoglycosides.
Moreover, histopathological evaluation of animals after pro-
longed treatment at low doses [57] showed also a lesser effect of
amikacin on proximal tubules, both for degenerative and regen-
erative alterations. All together, these data suggest that amika-
cm might be a lesser nephrotoxic aminoglycoside than gentami-
cm or tobramycin, when used in strictly comparable clinical
conditions.
Note added in proof
A recent clinical study [69] would tend to support the above-
mentioned conclusions.
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